Non-small-cell lung cancer and colorectal cancer
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1) Non-small-cell lung cancer patients who are treated with afatinib (giotrif) or erlotinib (tarceva) and colorectal cancer patients who are treated with cetuximab (erbitax). 2) PS is from 0 to 1. 3) Patients who agreed to participate in this study.
Exclusion criteria
Exclusion criteria: 1) Patients who have skin symptoms that influence skin functions such as atopic dermatitis. 2) Patients who receive treatments that influence skin functions such as steroids and antibacterial drugs. 3) Patients who are unable to control dependence. 4) Patients who are unable to respond to self-completed questionnaires. 5) Physicians decide it is inappropriate for the patients to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| <Assessment by devices> 1) Transepidermal water loss 2) Capacitance (stratum corneum-epidermal water) 3) Erythema & melanin index 4) Visia (Facial skin condition) <Visual assessment> NCI-CTC (ver. 4.0 Japanese version JCOG) <Self-completed questionnaires> Skindex 29 (QOL regarding skin symptoms) | — |
Countries
Japan
Contacts
National Cancer Center Hospital Appearance Support Center